Hennion & Walsh Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Hennion & Walsh Asset Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,630	Closed	-$63.6K	–	838
2023 Q3	$63.6K	Sell	13,630 -2,691	-16%	-$14.9K	﹤0.01%	793
2023 Q2	$87K	Sell	16,321 -15,526	-49%	-$125K	0.01%	789
2023 Q1	$313K	Sell	31,847 -917	-3%	-$15.6K	0.02%	632
2022 Q4	$613K	Buy	32,764 +3,371	+11%	+$76.4K	0.04%	453
2022 Q3	$608K	Sell	29,393 -707	-2%	-$18.1K	0.04%	437
2022 Q2	$625K	Buy	30,100 +1,303	+5%	+$36.7K	0.04%	441
2022 Q1	$1.24M	Buy	28,797 +5,905	+26%	+$266K	0.07%	295
2021 Q4	$1.37M	Buy	22,892 +9,490	+71%	+$760K	0.07%	293
2021 Q3	$1.15M	Buy	13,402 +4,587	+52%	+$460K	0.06%	324
2021 Q2	$981K	Buy	+8,815	New	+$847K	0.05%	364

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hennion & Walsh Asset Management's INO Position: Q4 2023 in Review

Hennion & Walsh Asset Management sold out of Inovio Pharmaceuticals (INO) in Q4 2023, closing a stake of 13,630 shares — an estimated $63.6K sold.

Hennion & Walsh Asset Management first reported a position in INO in Q2 2021 and held it in 10 quarters. The position peaked at $1.37M in Q4 2021. 113 funds tracked by Wall St. Rank hold INO as of Q4 2023.

Hennion & Walsh Asset Management reported no remaining Inovio Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 13,630 Inovio Pharmaceuticals shares in Q4 2023, an estimated $63.6K.
Hennion & Walsh Asset Management first reported a position in Inovio Pharmaceuticals in Q2 2021 and held it in 10 quarters.
Hennion & Walsh Asset Management's Inovio Pharmaceuticals position peaked at $1.37M in Q4 2021.
113 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2023, filed 10 Jan 2024.